InvestSMART

Actinogen Medical Limited (ASX:ACW)

ALERT: Price-sensitive ASX Announcement for ACW
Current share price for ACW : $0.063 0.021 (50%)+
Announcement
Release
20 Jul 2026 9:33AM
Price at Release
$0.042
Full Release
download
Summary
Actinogen Medical Limited announced promising results from its Xanamem phase 2 depression trial, published in the British Journal of Psychiatry. The trial involved patients with major depressive disorder and cognitive impairment, demonstrating significant antidepressant activity, particularly in those already on SSRI medication, although it did not show a cognitive benefit over placebo. Xanamem was reported to be safe and well-tolerated, indicating its potential as a novel antidepressant requiring further investigation. Additionally, Xanamem is being evaluated for Alzheimer's disease, with expectations for its antidepressant activity to improve patient quality of life.
Key Points
  • Actinogen Medical Limited's Xanamem phase 2 depression trial showed meaningful antidepressant activity.
  • The trial results were published in the British Journal of Psychiatry.
  • The trial involved patients with major depressive disorder and cognitive impairment.
  • Xanamem showed a significant antidepressant benefit versus placebo, especially in patients on SSRI medication.
  • The drug was safe and well-tolerated.
  • There was no observed benefit of Xanamem over placebo in cognitive improvement.
  • The trial results support further investigation of Xanamem as a novel antidepressant.
  • Xanamem is also being evaluated for Alzheimer's disease treatment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.